Dr. Paul Nghiem
Paul Nghiem, MD, PhD
Division Head
George F. Odland Endowed Chair in Dermatology

About us

The mission of the Division of Dermatology is to provide outstanding patient care, train and mentor future leaders in dermatology, and advance dermatologic knowledge. 

Our stories

Merkel cell carcinoma (MCC) is a rare, aggressive form of skin cancer. Avelumab has become the first FDA approved drug to treat it.

Merkel cell carcinoma research by Dr. Paul Nghiem is featured as one of the year’s major achievements in clinical cancer research and care.

Merkel cell carcinoma is a rare, aggressive type of skin cancer. It is less common than melanoma, but patients are three times more likely to die from it.